Jefferies Cuts Price Target on Merck (MRK) to $56; Reiterates Hold
- Techs buoy S&P, Nasdaq; Goldman pushes Dow to record high
- Buy Any Seasonal Market Weakness Ahead of Year End Rally - Oppenheimer (SPY)
- Oil hits 16-month high in buying rush after OPEC agreement
- Consolidated Communications (CNSL) to Acquire FairPoint Communications (FRP) in $1.5B Deal
- Berkshire Hathaway (BRK-A) Book Value Could Be Boosted by $29B from Trump Tax Plan - Analyst
Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.
Jefferies reiterated a Hold rating on Merck (NYSE: MRK), and cut the price target to $56.00 (from $57.00), as the company's growth remains constrained.
Analyst Jeffrey Holford commented, "MRK was over-rewarded for the failure of BMY's CM-026 study in our view. Whilst we see a c$3.3bn opportunity for Keytruda in NSCLC it is not enough to drive meaningful growth against upcoming LOEs. We expect competing IO combo data in 2017 will lower investor enthusiasm, though strong growth from Keytruda in Q4'16 may offset this to a degree."
Shares of Merck closed at $62.49 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Goldman Sachs Downgrades Marvell (MRVL) to Sell
- Jefferies Raises Price Target on Illinois Tool Works (ITW) Following Analyst Day
- Jefferies Cuts Price Target on Kroger (KR) to $30 Following 3Q and Guidance
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst EPS Change, Analyst PT Change
Related EntitiesJefferies & Co
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!